METHODS: A systematic search approach was used to look for eligible papers published until June 2023 in PubMed, Web of Science, and Embase, with a focus on overall survival (OS) and disease-free/recurrence-free survival (DFS/RFS). The prognostic potential of mGPS was assessed using hazard ratios (HRs) with corresponding 95% CIs.
RESULTS: A total of 15 papers comprising 2447 patients were included in this meta-analysis. The results demonstrated that, in patients with BTC, the high mGPS was associated with poorer OS (HR=1.49, 95% CI=1.35-1.65, P<0.001) and DFS/RFS (HR=3.23, 95%CI=1.98-5.26, P=0.193).
CONCLUSIONS: According to this meta-analysis, our study found that high mGPS was associated with poorer OS and DFS/RFS in patients with BTC.
方法:使用系统搜索方法来寻找截止到2023年6月在PubMed上发表的合格论文,WebofScience,和Embase,重点关注总生存期(OS)和无病/无复发生存期(DFS/RFS)。使用风险比(HRs)和相应的95%CIs评估mGPS的预后潜力。
结果:本荟萃分析共纳入15篇论文,包括2447名患者。结果表明,在BTC患者中,高mGPS与较差的OS(HR=1.49,95%CI=1.35-1.65,P<0.001)和DFS/RFS(HR=3.23,95CI=1.98-5.26,P=0.193)相关。
结论:根据本荟萃分析,我们的研究发现,在BTC患者中,高mGPS与较差的OS和DFS/RFS相关.